Stabilized human TRIM5α protects human T cells from HIV-1 infection

Molecular Therapy

Volumn 22, Issue 6, 2014, Pages 1084-1095

  Richardson, Max W ^a,b   Guo, Lili ^a,b   Xin, Frances ^a,b   Yang, Xiaolu ^a,b   Riley, James L ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HUMAN TRIPARTITE MOTIF PROTEIN 5; LENTIVIRUS VECTOR; RHESUS TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG; CARRIER PROTEIN; PROTEIN; RNA; TRIM5 PROTEIN, HUMAN; TRIM5(ALPHA) PROTEIN, RHESUS MONKEY; CD45 ANTIGEN; FLUORESCENT DYE; GREEN FLUORESCENT PROTEIN; HUMAN TRIPARTITE MOTIF PROTEIN 5 R323 332; MCHERRY; MESSENGER RNA; TRIPARTITE MOTIF PROTEIN 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROTECTION; CONTROLLED STUDY; GENE; GENE FUSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN VERSUS ANIMAL COMPARISON; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STABILITY; RHESUS MONKEY; STEADY STATE; TRIM5 ALPHA GENE; UBIQUITINATION; VIRUS REPLICATION; ANIMAL; CELL CULTURE; CYTOPLASM; DISEASE MODEL; GENETICS; GROWTH, DEVELOPMENT AND AGING; HIV INFECTIONS; IMMUNOLOGY; METABOLISM; TRANSPLANTATION; VIROLOGY; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; BINDING AFFINITY; BIOACCUMULATION; CD4 LYMPHOCYTE COUNT; CELL NUCLEUS INCLUSION BODY; ENGRAFTMENT; GENE EXPRESSION; GENETIC TRANSFECTION; HALF LIFE TIME; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOTHERAPY; IN VITRO STUDY; INFECTION PREVENTION; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; VIRUS CAPSID; VIRUS INHIBITION; VIRUS LOAD; WILD TYPE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; CARRIER PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOPLASM; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; MICE; PROTEIN STABILITY; PROTEINS; RNA; UBIQUITINATION;

EID: 84902123429     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.52     Document Type: Article

References (50)

1. Stremlau, M, Owens, CM, Perron, MJ, Kiessling, M, Autissier, P and Sodroski, J (2004). The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848-853. (Pubitemid 38297747)
2. Pertel, T, Hausmann, S, Morger, D, Züger, S, Guerra, J, Lascano, J et al. (2011). TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472: 361-365.
3. Anderson, JL, Campbell, EM, Wu, X, Vandegraaff, N, Engelman, A and Hope, TJ (2006). Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J Virol 80: 9754-9760. (Pubitemid 44435649)
4. Wu, X, Anderson, JL, Campbell, EM, Joseph, AM and Hope, TJ (2006). Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci USA 103: 7465-7470. (Pubitemid 43727856)
5. Ganser-Pornillos, BK, Chandrasekaran, V, Pornillos, O, Sodroski, JG, Sundquist, WI and Yeager, M (2011). Hexagonal assembly of a restricting TRIM5alpha protein. Proc Natl Acad Sci USA 108: 534-539.
6. Zhao, G, Ke, D, Vu, T, Ahn, J, Shah, VB, Yang, R et al. (2011). Rhesus TRIM5 disrupts the HIV-1 capsid at the inter-hexamer interfaces. PLoS Pathog 7: e1002009.
7. Langelier, CR, Sandrin, V, Eckert, DM, Christensen, DE, Chandrasekaran, V, Alam, SL et al. (2008). Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication. J Virol 82: 11682-11694.
8. Li, X and Sodroski, J (2008). The TRIM5alpha B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association. J Virol 82: 11495-11502.
9. Li, Y, Li, X, Stremlau, M, Lee, M and Sodroski, J (2006). Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection. J Virol 80: 6738-6744. (Pubitemid 44025173)
10. Stremlau, M, Perron, M, Lee, M, Li, Y, Song, B, Javanbakht, H et al. (2006). Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci USA 103: 5514-5519.
11. Black, LR and Aiken, C (2010). TRIM5alpha disrupts the structure of assembled HIV-1 capsid complexes in vitro. J Virol 84: 6564-6569.
12. Zhang, F, Hatziioannou, T, Perez-Caballero, D, Derse, D and Bieniasz, PD (2006). Antiretroviral potential of human tripartite motif-5 and related proteins. Virology 353: 396-409. (Pubitemid 44397135)
13. Li, X, Gold, B, O'hUigin, C, Diaz-Griffero, F, Song, B, Si, Z et al. (2007). Unique features of TRIM5alpha among closely related human TRIM family members. Virology 360: 419-433. (Pubitemid 46505024)
14. Stremlau, M, Perron, M, Welikala, S and Sodroski, J (2005). Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol 79: 3139-3145. (Pubitemid 40270592)
15. Chatterji, U, Bobardt, MD, Gaskill, P, Sheeter, D, Fox, H and Gallay, PA (2006). Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry. J Biol Chem 281: 37025-37033. (Pubitemid 46042173)
16. Maillard, PV, Zoete, V, Michielin, O and Trono, D (2011). Homology-based identification of capsid determinants that protect HIV1 from human TRIM5? restriction. J Biol Chem 286: 8128-8140.
17. Richardson, MW, Carroll, RG, Stremlau, M, Korokhov, N, Humeau, LM, Silvestri, G et al. (2008). Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha. J Virol 82: 11117-11128.
18. Zhao, K, Ishida, Y, Oleksyk, TK, Winkler, CA and Roca, AL (2012). Evidence for selection at HIV host susceptibility genes in a West Central African human population. BMC Evol Biol 12: 237.
19. Price, H, Lacap, P, Tuff, J, Wachihi, C, Kimani, J, Ball, TB et al. (2010). A TRIM5alpha exon 2 polymorphism is associated with protection from HIV-1 infection in the Pumwani sex worker cohort. AIDS 24: 1813-1821.
20. Goldschmidt, V, Bleiber, G, May, M, Martinez, R, Ortiz, M and Telenti, A; Swiss HIV Cohort Study (2006). Role of common human TRIM5alpha variants in HIV-1 disease progression. Retrovirology 3 54
21. Javanbakht, H, An, P, Gold, B, Petersen, DC, O'Huigin, C, Nelson, GW et al. (2006). Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology 354: 15-27. (Pubitemid 44468115)
22. Yap, MW, Nisole, S and Stoye, JP (2005). A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 15: 73-78. (Pubitemid 40084706)
23. Neagu, MR, Ziegler, P, Pertel, T, Strambio-De-Castillia, C, Grütter, C, Martinetti, G et al. (2009). Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J Clin Invest 119: 3035-3047.
24. Sastri, J, O'Connor, C, Danielson, CM, McRaven, M, Perez, P, Diaz-Griffero, F et al. (2010). Identification of residues within the L2 region of rhesus TRIM5alpha that are required for retroviral restriction and cytoplasmic body localization. Virology 405: 259-266.
25. Stepanenko, OV, Verkhusha, VV, Kazakov, VI, Shavlovsky, MM, Kuznetsova, IM, Uversky, VN et al. (2004). Comparative studies on the structure and stability of fluorescent proteins EGFP, zFP506, mRFP1,dimer2, and DsRed1. Biochemistry 43: 14913-14923. (Pubitemid 39587467)
26. Diaz-Griffero, F, Li, X, Javanbakht, H, Song, B, Welikala, S, Stremlau, M et al. (2006). Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology 349: 300-315. (Pubitemid 43796239)
27. Kornitzer, D (2002). Monitoring protein degradation. Methods Enzymol 351: 639-647. (Pubitemid 34615015)
28. Belle, A, Tanay, A, Bitincka, L, Shamir, R and O'Shea, EK (2006). Quantification of protein half-lives in the budding yeast proteome. Proc Natl Acad Sci USA 103: 13004-13009. (Pubitemid 44338907)
29. Yamauchi, K, Wada, K, Tanji, K, Tanaka, M and Kamitani, T (2008). Ubiquitination of E3 ubiquitin ligase TRIM5 alpha and its potential role. FEBS J 275: 1540-1555. (Pubitemid 351388800)
30. Kim, J, Tipper, C and Sodroski, J (2011). Role of TRIM5 RING domain E3 ubiquitin ligase activity in capsid disassembly, reverse transcription blockade, and restriction of simian immunodeficiency virus. J Virol 85: 8116-8132.
31. Lienlaf, M, Hayashi, F, Di Nunzio, F, Tochio, N, Kigawa, T, Yokoyama, S et al. (2011). Contribution of E3-ubiquitin ligase activity to HIV-1 restriction by TRIM5alpha(rh): structure of the RING domain of TRIM5alpha. J Virol 85: 8725-8737.
32. Battivelli, E, Lecossier, D, Matsuoka, S, Migraine, J, Clavel, F and Hance, AJ (2010). Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1. J Virol 84: 11010-11019.
33. Battivelli, E, Migraine, J, Lecossier, D, Matsuoka, S, Perez-Bercoff, D, Saragosti, S et al. (2011). Modulation of TRIM5alpha activity in human cells by alternatively spliced TRIM5 isoforms. J Virol 85: 7828-7835.
34. Battivelli, E, Migraine, J, Lecossier, D, Yeni, P, Clavel, F and Hance, AJ (2011). Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity. J Virol 85: 11846-11854.
35. Tissot, C and Mechti, N (1995). Molecular cloning of a new interferon-induced factor that represses human immunodeficiency virus type 1 long terminal repeat expression. J Biol Chem 270: 14891-14898.
36. Perez, EE, Wang, J, Miller, JC, Jouvenot, Y, Kim, KA, Liu, O et al. (2008). Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26: 808-816. (Pubitemid 351961450)
37. Sharp, PM and Hahn, BH (2011). Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 1: a006841.
38. Kirchhoff, F (2010). Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 8: 55-67.
39. Perron, MJ, Stremlau, M, Song, B, Ulm, W, Mulligan, RC and Sodroski, J (2004). TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc Natl Acad Sci USA 101: 11827-11832. (Pubitemid 39095379)
40. Towers, G, Bock, M, Martin, S, Takeuchi, Y, Stoye, JP and Danos, O (2000). A conserved mechanism of retrovirus restriction in mammals. Proc Natl Acad Sci USA 97: 12295-12299.
41. Lim, SY, Rogers, T, Chan, T, Whitney, JB, Kim, J, Sodroski, J et al. (2010). TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys. PLoS Pathog 6: e1000738.
42. Chackerian, B, Long, EM, Luciw, PA and Overbaugh, J (1997). Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J Virol 71: 3932-3939. (Pubitemid 27172408)
43. Hofmann, W, Schubert, D, LaBonte, J, Munson, L, Gibson, S, Scammell, J et al. (1999). Species-specific, postentry barriers to primate immunodeficiency virus infection. J Virol 73: 10020-10028.
44. Johnson, WE and Sawyer, SL (2009). Molecular evolution of the antiretroviral TRIM5 gene. Immunogenetics 61: 163-176.
45. Kaiser, SM, Malik, HS and Emerman, M (2007). Restriction of an extinct retrovirus by the human TRIM5alpha antiviral protein. Science 316: 1756-1758. (Pubitemid 46988552)
46. Allers, K, Hütter, G, Hofmann, J, Loddenkemper, C, Rieger, K, Thiel, E et al. (2011). Evidence for the cure of HIV infection by CCR532/32 stem cell transplantation. Blood 117: 2791-2799.
47. Holt, N, Wang, J, Kim, K, Friedman, G, Wang, X, Taupin, V et al. (2010). Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28: 839-847.
48. Anderson, J and Akkina, R (2005). TRIM5alpharh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages. Mol Ther 12: 687-696. (Pubitemid 41350150)
49. Sakuma, R, Mael, AA and Ikeda, Y (2007). Alpha interferon enhances TRIM5alphamediated antiviral activities in human and rhesus monkey cells. J Virol 81: 10201-10206. (Pubitemid 350067723)
50. Barr, SD, Smiley, JR and Bushman, FD (2008). The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog 4: e1000007.